Today: 9 April 2026
Subscribe
Browse Category

BSE:MEESHO 10 December 2025 - 12 December 2025

Meesho Limited Share Price Today: Stock Slips on Day 3 After Blockbuster IPO — Latest News, Forecasts and Analyst Targets (Dec 12, 2025)

Meesho Limited Share Price Today: Stock Slips on Day 3 After Blockbuster IPO — Latest News, Forecasts and Analyst Targets (Dec 12, 2025)

Meesho shares fell over 3% in early Mumbai trading Friday, retreating after sharp gains in the first two sessions following its IPO. By early afternoon, the stock hovered near ₹161–₹162, down from a debut price of ₹162.5 and well above the ₹111 IPO price. The company raised about ₹5,421 crore in the offering, which was subscribed nearly 80 times. Intraday swings showed continued volatility as investors sought a stable price.
12 December 2025
···
Meesho Share Price Today: 46% Listing Premium, ₹200 Target and What the Blockbuster IPO Means for Investors

Meesho Share Price Today: 46% Listing Premium, ₹200 Target and What the Blockbuster IPO Means for Investors

Meesho Limited debuted on the NSE at ₹162.50 per share, about 46% above its IPO price of ₹111, and hit an intraday high near ₹177.5. By early afternoon, shares traded around ₹170, up 53% from the issue price, with over ₹6,000 crore traded and volumes above 35 crore shares. Market capitalization on listing day stood at roughly ₹77,000 crore. The IPO was subscribed around 80 times overall.
10 December 2025
···

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Go toTop